We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Regular Thyroid Testing Recommended Regardless of Diabetes Type

By LabMedica International staff writers
Posted on 05 Mar 2020
Print article
Image: Biochemical thyroid screening is recommended as part of routine management for type 1 and type 2 diabetes (Photo courtesy of Alzyme).
Image: Biochemical thyroid screening is recommended as part of routine management for type 1 and type 2 diabetes (Photo courtesy of Alzyme).
Thyroid dysfunction is common among people with diabetes regardless of type, suggesting that biochemical thyroid screening should be a part of routine management for those with type 1 and type 2. A recent study has determined the prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults.

The American Diabetes Association (ADA) recommends universal screening for thyroid dysfunction in type 1 diabetes. The ADA previously recommended thyroid screening for women aged at least 50 years with type 2 diabetes; however, the current ADA guideline and that of the UK National Institute for Health and Care Excellence do not recommend thyroid function monitoring in type 2 diabetes.

Scientists at the University of Western Australia Medical School (Fremantle, Australia) in an observational study, analyzed data from 1,617 adults participating in the Fremantle Diabetes Study Phase II, including 130 (8%) with type 1 diabetes, 1,408 (87.1%) with type 2 diabetes and 79 (4.9%) with latent autoimmune diabetes in adults (LADA). The team assessed thyroid-stimulating hormone (TSH) and free thyroxine at baseline between 2008 and 2011 and in those attending follow-up at four years.

The investigators reported that the prevalence of known thyroid disease was 11.7% (189/1,617). Of the remaining 1,428 participants, 5.1% (73/1,428) had biochemical evidence of subclinical hypothyroidism, 1.1% (15/1428) overt hypothyroidism, 0.1% (2/1428) subclinical hyperthyroidism and 0.2% (3/1428) overt hyperthyroidism, representing an overall baseline prevalence of thyroid disease of 17.4% (282/1,617). During 5,694 patient‐years of follow‐up, 25 (3.0%) of the 844 with a normal baseline TSH and follow‐up data developed known thyroid disease. Of the remaining 819, 3.4% developed subclinical hypothyroidism, 0.2% overt hypothyroidism and 0.5% subclinical hyperthyroidism.

Paul Chubb, PhD, FFSc (RCPA), an adjunct associate professor and a co-author of the study said, “The prevalence of thyroid disease is about the same regardless of the type of diabetes, mainly because the average age of people with type 2 diabetes was higher than that of those with type 1 diabetes. However, we also found that mild abnormalities of thyroid function test results were frequently transient, so that appropriate repeat testing and careful interpretation of the results is needed if overdiagnosis is to be avoided.”

The authors concluded that thyroid dysfunction, known or detected through screening, is common in diabetes. These data suggest the need for periodic clinical and biochemical screening for thyroid disease in all types of diabetes. The study was published on January 27, 2020 in the journal Clinical Endocrinology.

Related Links:
University of Western Australia Medical School

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.